Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis SuppurativaContributed by: Business WireLogoTagsScienceBiotechnologyResearchPharmaceuticalGeneral HealthHealthFDAClinical TrialsEuropean Commission approval Povofortay